Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden

Standard

Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. / Weiberg, Desiree; Thackeray, James T; Daum, Guenter; Sohns, Jan M; Kropf, Saskia; Wester, Hans-Juergen; Ross, Tobias L; Bengel, Frank M; Derlin, Thorsten.

In: J NUCL MED, Vol. 59, No. 2, 02.2018, p. 266-272.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{cc408eafac154ff992ed8299f2cb768d,
title = "Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden",
abstract = "The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXCR4 ligand for PET. Methods: The data for 51 patients who underwent 68Ga-pentixafor PET/CT for noncardiovascular indications were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed qualitatively and semiquantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with calcified plaque burden and cardiovascular risk factors. Results: Focal arterial uptake of 68Ga-pentixafor was seen at 1,411 sites in 51 (100%) of patients. 68Ga-pentixafor uptake was significantly associated with calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004). Both the prevalence (P < 0.0001) and the signal intensity (P = 0.009) of 68Ga-pentixafor uptake increased as the number of risk factors increased. Conclusion:68Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic arterial wall. Arterial wall 68Ga-pentixafor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to the presence of cardiovascular risk factors. 68Ga-pentixafor signal is higher in patients with a high-risk profile and may hold promise for identification of vulnerable plaque.",
keywords = "Adult, Aged, Aged, 80 and over, Biological Transport, Calcinosis/complications, Coordination Complexes/metabolism, Female, Gene Expression Regulation, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Peptides, Cyclic/metabolism, Plaque, Atherosclerotic/complications, Receptors, CXCR4/metabolism, Retrospective Studies, Risk Factors, Young Adult",
author = "Desiree Weiberg and Thackeray, {James T} and Guenter Daum and Sohns, {Jan M} and Saskia Kropf and Hans-Juergen Wester and Ross, {Tobias L} and Bengel, {Frank M} and Thorsten Derlin",
note = "{\textcopyright} 2018 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2018",
month = feb,
doi = "10.2967/jnumed.117.196485",
language = "English",
volume = "59",
pages = "266--272",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden

AU - Weiberg, Desiree

AU - Thackeray, James T

AU - Daum, Guenter

AU - Sohns, Jan M

AU - Kropf, Saskia

AU - Wester, Hans-Juergen

AU - Ross, Tobias L

AU - Bengel, Frank M

AU - Derlin, Thorsten

N1 - © 2018 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2018/2

Y1 - 2018/2

N2 - The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXCR4 ligand for PET. Methods: The data for 51 patients who underwent 68Ga-pentixafor PET/CT for noncardiovascular indications were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed qualitatively and semiquantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with calcified plaque burden and cardiovascular risk factors. Results: Focal arterial uptake of 68Ga-pentixafor was seen at 1,411 sites in 51 (100%) of patients. 68Ga-pentixafor uptake was significantly associated with calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004). Both the prevalence (P < 0.0001) and the signal intensity (P = 0.009) of 68Ga-pentixafor uptake increased as the number of risk factors increased. Conclusion:68Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic arterial wall. Arterial wall 68Ga-pentixafor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to the presence of cardiovascular risk factors. 68Ga-pentixafor signal is higher in patients with a high-risk profile and may hold promise for identification of vulnerable plaque.

AB - The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXCR4 ligand for PET. Methods: The data for 51 patients who underwent 68Ga-pentixafor PET/CT for noncardiovascular indications were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed qualitatively and semiquantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with calcified plaque burden and cardiovascular risk factors. Results: Focal arterial uptake of 68Ga-pentixafor was seen at 1,411 sites in 51 (100%) of patients. 68Ga-pentixafor uptake was significantly associated with calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004). Both the prevalence (P < 0.0001) and the signal intensity (P = 0.009) of 68Ga-pentixafor uptake increased as the number of risk factors increased. Conclusion:68Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic arterial wall. Arterial wall 68Ga-pentixafor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to the presence of cardiovascular risk factors. 68Ga-pentixafor signal is higher in patients with a high-risk profile and may hold promise for identification of vulnerable plaque.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biological Transport

KW - Calcinosis/complications

KW - Coordination Complexes/metabolism

KW - Female

KW - Gene Expression Regulation

KW - Humans

KW - Image Processing, Computer-Assisted

KW - Male

KW - Middle Aged

KW - Peptides, Cyclic/metabolism

KW - Plaque, Atherosclerotic/complications

KW - Receptors, CXCR4/metabolism

KW - Retrospective Studies

KW - Risk Factors

KW - Young Adult

U2 - 10.2967/jnumed.117.196485

DO - 10.2967/jnumed.117.196485

M3 - SCORING: Journal article

C2 - 28775206

VL - 59

SP - 266

EP - 272

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 2

ER -